Multicenter clinical study of “sandwich therapy” based on SMILE chemotherapy regimen in the treatment of extranodal NK/T-cell lymphoma (nasal type) in children-(CCCG -ENKTL - 2021)

Multicenter clinical study of xtranodal NK/T-cell lymphoma (nasal type) in children

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059545

Enrollment

Unknown

Registered

2022-05-04

Start date

2022-05-03

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extranodal NK/T-cell lymphoma (nasal type)

Interventions

Intervention group:"Sandwich therapy" based on SMILE chemotherapy

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. New cases confirmed by histopathology; 2. The age of initial diagnosis is 1-18 years old (cases under 1 year old are rare, and the drug dose should be adjusted accordingly); 3. The organ function of the children meets the requirements of radiotherapy and chemotherapy; 4. The child and guardian agree to participate in the clinical trial and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. NK cell leukemia and precursor NK cell tumor; 2. Patients with other basic diseases with organ dysfunction not caused by this disease; 3. Those who have received other chemotherapy regimens; 4. The guardian of the child is unwilling to accept the treatment of this scheme.

Design outcomes

Primary

Measure	Time frame
Overall survival;Progression free survival;	—

Secondary

Measure	Time frame
Adverse reaction events;	—

Countries

China

Contacts

Public ContactXia Guo

West China Second University Hospital, Sichuan University

guoxkl@163.com+86 139 8203 9185

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026